Results 221 to 230 of about 24,524 (277)
Some of the next articles are maybe not open access.
Sulfonylurea receptors and mechanism of sulfonylurea action
Experimental and Clinical Endocrinology & Diabetes, 2009Binding of hypoglycemic sulfonylureas and their analogues to the sulfonylurea receptor in the beta-cell plasma membrane mediates closure of the ATP-sensitive K+-channel (KATP-channel) and thereby stimulation of insulin release. The sulfonylurea receptor is a member of the traffic ATPase family with two intracellular nucleotide binding folds.
U, Panten +2 more
openaire +2 more sources
The pharmacology of sulfonylureas
The American Journal of Medicine, 1981In this report we review the pharmacology of the hypoglycemic sulfonylurea drugs. The early work with sulfonylureas is briefly described. The pharmacokinetics of first-generation sulfonylureas, such as tolbutamide, chlorpropamide, acetohexamide and tolazamide, are described.
T G, Skillman, J M, Feldman
openaire +2 more sources
Annual Review of Medicine, 1974
Sulfonylurea drugs such as tolbutamide have been used extensively in the treatment of patients with diabetes mellitus. The recent report of the University Group Dia betes Program (UGDP) (1) suggested an association of tolbutamide therapy with increased incidence of cardiovascular deaths.
G S, Levey, K C, Lasseter, R F, Palmer
openaire +2 more sources
Sulfonylurea drugs such as tolbutamide have been used extensively in the treatment of patients with diabetes mellitus. The recent report of the University Group Dia betes Program (UGDP) (1) suggested an association of tolbutamide therapy with increased incidence of cardiovascular deaths.
G S, Levey, K C, Lasseter, R F, Palmer
openaire +2 more sources
Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristics [PDF]
Biochimica Et Biophysica Acta - Biomembranes, 1994 Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with ...
Gunter Müller, Werner Kramer
exaly +2 more sources
Endocrinology and Metabolism Clinics of North America, 1997
Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in ...
openaire +2 more sources
Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in ...
openaire +2 more sources
Diabetes Care, 1992
Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion.
openaire +2 more sources
Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion.
openaire +2 more sources
Potential Hypoglycemic Sulfonylureas
Journal of Pharmaceutical Sciences, 1964A series of N ′-alkyl- N - p -phenylbenzenesulfonylureas and N , N ′-bis ( N -alkylcarbamyl) 4,4′-biphenyldisulfonamides has been prepared for pharmacological studies of their hypoglycemic activities.
K A, NIEFORTH, G L, JENKINS, A M, KNEVEL
openaire +2 more sources
Acta medica portuguesa, 1990
Oral antidiabetics are an important aspect of treatment in many diabetics and in the last few years with new developments in the knowledge of type II diabetes physiopathology, there has been a lot of interest in their actions mechanisms. Oral therapy is nevertheless a mere complement which needs to be fitted into a wider group of measures: diabetics ...
openaire +3 more sources
Oral antidiabetics are an important aspect of treatment in many diabetics and in the last few years with new developments in the knowledge of type II diabetes physiopathology, there has been a lot of interest in their actions mechanisms. Oral therapy is nevertheless a mere complement which needs to be fitted into a wider group of measures: diabetics ...
openaire +3 more sources
Sulfonylureas have been a mainstay in the pharmacologic treatment of T2D for over 60 years. The first-generation sulfonylureas (e.g., chlorpropamide, tolbutamide, and tolazamide) are no longer available in the United States. With the availability of many noninsulin classes of medications for T2D, sulfonylurea usage is on the decline, yet their use ...
Elmo M. Beyer +3 more
openaire +2 more sources
Elmo M. Beyer +3 more
openaire +2 more sources
Hepatic effect of sulfonylureas
Metabolism, 1970Abstract The sulfonylureas, tolbutamide, tolazamide and acetohexamide significantly diminish uptake of insulin by the isolated perfused rat liver, whereas the nonhypoglycemic metabolite of tolbutamide, carboxytolbutamide, has no such effect. These results suggest that the sustained action of the sulfonylureas may in part be due to reduced hepatic ...
A, Marshall, R L, Gingerich, P H, Wright
openaire +2 more sources